Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability
Authors' conclusion
These data demonstrate the efficacy and tolerability of ropinirole for the treatment of hyperprolactinemia in patients with microprolactinomas and idiopathic hyperprolactinemia and suggest ropinirole may represent a novel therapeutic alternative for treating hyperprolactinemic disorders in patients with ergot DA intolerance.
Study context
- Population
- Hyperprolactinemic women; 2 DA naive, 6 ergot DA intolerant, 1 known ergot DA resistance; baseline prolactin (PRL) 126.2 ± 41.4 ng/mL (SEM)7 in extension study
- Participants
- 12 women
- Outcome
- PRL normalization
Methodological detailsopen-label, 6-month, extension study up to 17 months
- Open-label
- 6-month
- Extension study up to 17 months
Main finding
As reported in the abstract
Ropinirole
50%
6 of 12
- Median effective total daily dose (TDD)
- 1 mg/d
- Ergot DA intolerant among those achieving PRL normalization
- 83%
Further findings
Persistent partial biochemical response (PRL reduction >50% from baseline)
- Participants with persistent partial biochemical response
- 17%
Resumption of menses in amenorrheic patients · during treatment
- Menses resumed in amenorrheic patients
- 67%
Resolution of galactorrhea · during treatment
- Galactorrhea resolved
- 67%
Ergot DA intolerance among patients achieving PRL normalization
- Ergot DA intolerant among those achieving PRL normalization
- 83%
Safety
| Outcome | Values |
|---|---|
| Adverse effects | Ropinirole 92% |
Adverse effects
- Mild adverse effects; no discontinuation due to intolerance, incl. among the 50% with prior ergot DA intolerance and discontinuation
Original publication
Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability. J Clin Endocrinol Metab. Published 16 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →